FIELD: biotechnology.
SUBSTANCE: invention relates to the use of a polypeptide SEQ ID NO: 4 in the treatment and/or prevention of an ophthalmic disorder in a mammalian subject, wherein the ophthalmic disorder includes damage and/or impairment of the optic nerve or where the ophthalmic disorder is characterized by a disorder of retinal ganglion cells. The invention also relates to a composition for the treatment and/or prevention of an ophthalmic disorder in a mammalian subject, comprising a polypeptide SEQ ID NO: 4, wherein the ophthalmic disorder includes damage and/or disruption of the optic nerve, or wherein the ophthalmic disorder is characterized by a disorder of retinal ganglion cells.
EFFECT: invention enables effective use of the compositions for the treatment and/or prevention of an ophthalmic disorder in a mammalian subject, wherein the ophthalmic disorder includes damage and/or impairment of the optic nerve or where the ophthalmic disorder is characterized by a disorder of retinal ganglion cells.
19 cl, 7 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | 2019 |
|
RU2799211C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| GENE THERAPY | 2016 |
|
RU2740038C2 |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2718047C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| TREATMENT OF RETINITIS PIGMENTOSA | 2016 |
|
RU2737049C2 |
| GENETIC STRUCTURE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE | 2018 |
|
RU2757932C2 |
| VIRIONS OF AN ADENO-ASSOCIATED VIRUS WITH A VARIANT CAPSID AND METHODS FOR USING THEM | 2017 |
|
RU2742724C1 |
